Vitamin D Status in Patients with Systemic Lupus Erythematosus in Serbia: Correlation with Disease Activity and Clinical Manifestations by Miskovic, Rada et al.
 _______________________________________________________________________________________________________________________________ 
  256                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
 
 
ID Design 2012/DOOEL Skopje 
Open Access Macedonian Journal of Medical Sciences. 2015 Jun 15; 3(2):256-261. 
http://dx.doi.org/10.3889/oamjms.2015.052 
Clinical Science 
  
 
 
Vitamin D Status in Patients with Systemic Lupus Erythematosus 
in Serbia: Correlation with Disease Activity and Clinical 
Manifestations 
 
 
Rada Miskovic
*
, Aleksandra Plavsic, Sanvila Raskovic, Zikica Jovicic, Jasna Bolpacic 
 
Clinical Center of Serbia, Clinic for Allergology and Immunology, Belgrade, Serbia 
 
Citation: Miskovic R, Plavsic A, Raskovic S, Jovicic Z, 
Bolpacic J. Vitamin D Status in Patients with Systemic 
Lupus Erythematosus in Serbia: Correlation with Disease 
Activity and Clinical Manifestations. OA Maced J Med Sci. 
2015 Jun 15; 3(2):256-261. 
http://dx.doi.org/10.3889/oamjms.2015.052 
Key words: SLE; vitamin D; disease activity; 
glucocorticoids; vitamin D supplements. 
*
Correspondence: Dr. Rada Miskovic. Clinical Center of 
Serbia, Clinic for Allergology and Immunology, Koste 
Todorovica 2, Belgrade 11000, Serbia. E-Mail: 
rada_delic@hotmail.com 
Received: 21-Mar-2015; Revised: 28-Apr-2015; 
Accepted: 29-Apr-2015; Online first: 04-May-2015 
Copyright: © 2015 Rada Miskovic, Aleksandra Plavsic, 
Sanvila Raskovic, Zikica Jovicic, Jasna Bolpacic. This is 
an open access article distributed under the terms of the 
Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are 
credited. 
Competing Interests: The authors have declared that no 
competing interests exist. 
 
 
 
 
 
 
 
Abstract  
BACKGROUND: Numerous studies indicate potential role of vitamin D as an important factor in the 
development of many autoimmune diseases including systemic lupus erythematosus (SLE). 
Patients with SLE are especially prone to the development of vitamin D deficiency due to the nature 
of their illness.  
AIM: The aims of our study were to determine the prevalence of vitamin D insufficiency and 
deficiency in patients with SLE in Serbia, to identify clinical variables associated with vitamin D 
status and to examine the impact of vitamin D status on disease activity and presence of specific 
lupus autoantibodies.  
MATERIAL AND METHODS: The study included 46 patients with SLE. Serum 25(OH)D 
concentration was measured by electrohemiluminiscent immunoassay.  
RESULTS: The mean serum concentration of 25(OH)D was 11.9 ± 7.3 ng/ml. The prevalence of 
insufficiency was 32.6%, while the prevalence of deficiency was 67.4%. There was no association 
between vitamin D status and photosensitivity, skin lesions, arthritis and lupus nephritis. Vitamin D 
status was not associated with the presence of specific autoantibodies. There was no correlation 
between disease activity assessed by SLEDAI scale with the concentration of 25(OH)D. Patients 
who used vitamin D supplements and calcium did not have a significantly higher concentration of 
25(OH)D.  
CONCLUSION: In conclusion, vitamin D deficiency is common in patients with SLE.  
 
 
 
Introduction 
 
Vitamin D is a liposoluble hormone with an 
essential role in the metabolism of calcium and 
phosphorus and bone mineralization. The main 
source of vitamin D is endogenous synthesis in the 
skin under the action of ultraviolet B rays, after which 
it gradually undergoes the process of hydroxylation, 
first in the liver when 25-hydroxy-vitamin D (25(OH)D) 
is produced, and then in the kidneys to make the 
active form of vitamin D - 1,25-dihydroxy-vitamin D 
(1,25(OH)2D). Smaller amounts of vitamin D come 
from food and supplements [1]. 
The role of vitamin D in the immune system 
was discovered in the 1980s when it was shown that 
antigen-presenting cells and lymphocytes express 
receptor for vitamin D (VDR). Further studies have 
established that many cells of the immune system 
have enzymes responsible for the metabolism of 
vitamin D which enables them to produce the active 
form of vitamin D in the microenvironment of lymph 
tissues. The effect of vitamin D on dendritic cells 
(DCs) is particulary important in autoimmunity. 
Vitamin D inhibits differentiation and promotes the 
formation of tolerogenic DCs with immature 
phenotype. It suppresses the differentiation of Th1 
lymphocytes, stimulates T regulatory cells, reduces 
the production of autoantibodies and release of 
inflammatory mediators [2-4]. There are evidence that 
vitamin D suppresses the expression of "interferon 
signature" as an important mechanism in the SLE 
pathogenesis [5]. Studies on several animal models of 
lupus showed that administration of vitamin D can 
lead to the improvement of various disease 
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manifestations [6].  
Numerous studies have found a high 
prevalence of vitamin D deficiency in patients with 
SLE. Some of the possible reasons for this are 
photosensitivity and application of sunscreen with a 
high sun protection factor, kidney damage, chronic 
glucocorticoids therapy, the use of the antimalarials 
[7]. Many authors point to the association between 
higher disease activity and vitamin D deficiency [8, 9]. 
However, in some studies, this association was not 
found [10].  
Our study was designed as a cross sectional 
study with the following objectives: (1) to determine 
the prevalence of vitamin D deficiency and 
insufficiency in SLE patients; (2) to examine the 
association between selected clinical manifestations 
of SLE with the vitamin D status; (3) to examine the 
association between vitamin D status with the 
presence of specific lupus autoantibodies in the serum 
of SLE patients; and (4) to examine the association 
between SLE activity and vitamin D status. 
 
 
Materials and Methods 
 
Subjects and variables 
The study included 46 consecutive SLE 
inpatients at the Clinic for Allergology and 
Immunology, Clinical Center of Serbia during the 
period from May to October 2011. All patients fulfilled 
at least 4 of 11 American College of Rheumatology 
(ACR) criteria from 1997 for the diagnosis of SLE. 
Exclusion criteria were: pregnancy and lactation 
period, elevated serum creatinine and diagnosis of 
malignant diseases or suspected malignancy. The 
study was approved by the Ethical committee of the 
Clinical Center of Serbia. 
The following variables were recorded: age, 
sex, duration of SLE, photosensitivity, skin changes, 
active arthritis, and activity of lupus nephritis and use 
of glucocorticoids (GC), antimalarials and vitamin D 
and calcium supplements. All patients underwent 
following laboratory analyzes: complete blood count 
with differential leukocyte formula, standard 
biochemical analysis, concentration of parathyroid 
hormone, urinalysis, 24h-proteinuria, creatinine 
clearance, C3 and C4 concentration, presence of the 
following autoantibodies: ANA, anti-ds-DNA, anti-SSA, 
anticardiolipin IgG and IgM Ab ( aCL). Disease activity 
was evaluated using SLEDAI (SLE Disease Activity 
Index) scale. 
 
Determination of vitamin D status 
Vitamin D status was determined by 
measuring serum 25(OH)D concentration, which is the 
main circulating form of vitamin D. We used cut-off 
values recommended by the laboratory where the 
analysis was preformed: insufficiency was defined as 
serum 25(OH)D concentration less than or equal 
30ng/ml and greater than 15ng/ml, while 25(OH)D 
concentration less than or equal to 15 ng/ml was 
defined as a deficiency. Blood samples from all 
patients were taken during summer period (May to 
October). The 25(OH)D concentration was measured 
using ECLIA (electrochemiluminescent immunoassay) 
on the Roche Cobas E601 apparatus. 
 
Statistical analysis 
The data collected were processed using 
standard statistical methods using statistical software 
SPSS 14:00 for Windows (SPSS Inc., Chicago, IL, 
USA).We used following statistical methods: 
descriptive statistics, methods for testing the 
significance of differences (t-test, chi-square test, 
ANOVA) and methods for assessing correlation 
(Pearson and Spearman correlation). Prevalence of 
vitamin D deficiency and insufficiency was calculated 
as the ratio between the number of patients with a 
deficiency or insufficiency and the total number of 
subjects. All patients had reduced serum 25(OH)D 
concentration, therefore we compared patients with 
vitamin D insufficiency to patients with vitamin D 
deficiency. 
 
 
Results 
 
Description of the study group 
Forty-six patients with a mean age of 45.4 ± 
12.5 (21-68) years were included in the study. There 
were 40 (86.9%) female and 6 (13.1%) male patients. 
Mean disease duration was 6.15 (0-29) years. Table 1 
shows main clinical, laboratory and therapeutic 
characteristics of the study group. 
Table 1: Clinical, laboratory and therapeutic characteristics of 
the study group 
Variable Value 
Photosensitivity (n /%) 27 (58.7%) 
Skin lesions (n/%) 9 (19.6%) 
Arthritis (n/%) 15 (32.6%) 
Lupus nephritis (n/%) 22 (47.8%) 
Hematologic manifestations (n/%) 14 (30.4%) 
Serositis (n/%) 3 (6.5%) 
Neurolupus (n/%) 5 (10.9%) 
Serum calcium (mmol/l, range) 2.23 (1.93-2.58) 
Parathyroid hormone (pg/ml, range) 56 (17-141) 
Creatinin clearance (ml/min, range) 75.1 (28.08-136.96) 
ANA (n, %) 36 (78.3%) 
anti-ds-DNK Ab (n, %) 11 (24.0%) 
anti-SSA Ab  (n, %) 18 (39.1%) 
aCL IgG (n, %) 6 (13.0%) 
aCL IgM (n, %) 10 (21.7%) 
SLEDAI 0 (n,%) 10 (21.7% ) 
SLEDAI 1-7 (n,%) 21 (45.7%) 
SLEDAI ≥8 15 (32.6% ) 
Current GC therapy (n, %) 41 (89.%) 
Average prednisolone dose  (g, range) 0.015 (0-0.1) 
Average duration of GC therapy ( y, range) 6.15 (0-29) 
Current antimalarials (n, %) 9 (19.6%) 
Current vitamin D and calcium supplements (n,%) 22 (47.8%) 
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Prevalence of vitamin D deficiency and 
insufficiency 
Mean serum 25(OH)D concentration was 11.9 
± 7.3 ng/ml (0-25.7 ng/ml). All patients had reduced 
serum 25(OH)D concentration. Figure 1 shows 
distribution of patients according to vitamin D status.  
0 (0%)
 15 (32.6%)
31 (67.4%)
0
5
10
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Figure 1: Distribution of patients according to vitamin D status 
 
The average 25(OH)D concentration in the 
insufficiency group was 20.8 ± 3.2 ng/ml, and in the 
deficiency group we measured 7.5 ± 3.9 ng/ml. There 
was a statistically significant negative correlation 
between serum 25(OH)D and PTH serum 
concentration (r = - 0.434, p = 0.003). 
 
 
Characteristics of patients according to the 
vitamin D status 
Patients in the deficiency group did not differ 
significantly with respect to age (t = 0.889, p = 0.378), 
SLE duration (t = 1.73, p = 0.09) and gender (² = 
0.002, p = 0.964) from those in the insufficiency 
group. Table 2 shows distribution of selected 
demographic, clinical and laboratory variables 
according to the vitamin D status. 
Table 2: Distribution of demographic, clinical and laboratory 
variables according to the vitamin D status 
Variable Insufficiency Deficiency 
Age 43.1 ± 13.85 46.6 ± 11.91 
Female gender 13/15 (86.7%) 27/31 (87.1%) 
SLE duration 8.3 ± 7.62 5.1 ± 5.04 
Photosensitivity 8/15 (53.3%) 19/31 (61.3%) 
Skin lesions 3/15 (20.0%) 6/31   (19.4%) 
Arthritis 6/15 (40.0%) 9/31   (29.0%) 
Lupus nephritis 5/15 (33.3%) 17/31 (54.8%) 
anti-ds-DNK Ab 2/15 (13.4%) 9/31   (29.0%) 
anti-SSA Ab 4/15 (26.7%) 14/31 (45.2%) 
SLEDAI 0 2/15 (13.4%) 8/31   (25.8%) 
SLEDAI 1-7 8/15 (53.3%) 13/31 (41.9%) 
SLEDAI ≥ 8 5/15 (33.3%) 10/31 (32.2%) 
Current prednisolone dose in g 0.0127 0.0165 
Duration of GC therapy (years) 8.3 5.1 
Antimalarials 2/15 (13.4%) 7/31 (22.6%) 
Vitamin D and calcium     supplements 9/15 (60%) 13/31 (41.9%) 
 
 
Vitamin D and clinical manifestations of SLE 
We examined the association of specific 
clinical manifestations with vitamin D status. There 
was no statistically significant difference in the 
incidence of photosensitivity (² = 0.264, p = 0.607), 
skin lesions (² = 0.003, p = 0.959) and arthritis (² = 
0.553, p = 0.457) between deficiency and insufficiency 
group. There was a higher incidence of lupus nephritis 
in the vitamin D deficiency group (54.8% vs 33.3%), 
but it was not statistically significant (² = 1.874, p = 
0.171).  
 
 
Vitamin D and presence of specific lupus 
autoantibodies 
We investigated the influence of 25(OH)D 
concentration on the presence of specific lupus 
autoantibodies. None of tested autoantibodies showed 
a statistically significant association with vitamin D 
status (ANA - ² = 0.924, p = 0.338; anti-ds-DNA At - 
² = 1.369, p = 0.241; anti-SSA At - ² = 1.452, p = 
0228; aCL IgG - ² = 0.95, p = 0.329; aCL IgM class - 
² = 0.318, p = 0.572). Patients who had positive anti-
ds-DNA and anti-SSA antibodies had lower mean 
25(OH)D concentration, but this difference did not 
reach statistical significance (anti-ds-DNA At - t = 
1.482, p = 0.145; anti-SSA At - t = 1.015, p = 0.316). 
 
Vitamin D and SLE activity 
There was no correlation between 25(OH)D 
concentration and SLEDAI score (Pearson correlation 
coefficient 0.194, p = 0.195). Comparing the average 
25(OH)D concentration by groups of SLEDAI score, 
there was no statistically significant difference 
between these groups (ANOVA, F = 1.406, p = 
0.256). Mean SLEDAI score in the insufficiency group 
was not statistically significant different from the score 
in the vitamin D deficiency group (6.6 ± 7.34 vs 5.2 ± 
4.61, t = 0.814, p = 0.42). 
 
Vitamin D and drugs use 
Most of our patients used GC (41/46, 89.1%). 
The 25(OH)D concentration did not correlate to the 
current prednisolone dose (Spearman correlation 
coefficient of -0.116, p = 0.442) or to the duration of 
GC therapy (Spearman correlation coefficient 0.184, p 
= 0.221). There were no statistically significant 
differences between vitamin D deficiency and 
insufficiency group in relation to the current 
prednisolone dose (p = 0.45) and duration of GC 
therapy (p = 0.10). 
According to the incidence of antimalarial use, 
there was no statistically significant difference 
between the two groups (² = 0.549, p = 0.458). The 
average 25(OH)D concentration in patients who used 
antimalarials was 10.1 ng/ml, which was less than in 
those who did not used them in therapy (12.3 ng/ml), 
but this was not statistically significant (t = 0.802, p = 
0.427). 
Almost half of the patients (47.8%) used 
vitamin D (400-800 IU cholecalciferol) and calcium 
 Miskovic et al. Vitamin D Status in Patients with Systemic Lupus Erythematosus in Serbia 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2015 Jun 15; 3(2):256-261.                                                                                                                                                                         259 
 
supplements. Those who used supplements did not 
have significantly higher serum 25(OH)D 
concentration (12.7 vs. 11.67 ng/ml, t = 0.185, p = 
0.854). 
 
 
Discussion 
 
Patients with SLE have multiple risk factors 
for vitamin D deficiency. However, data on the 
prevalence of vitamin D deficiency in SLE show 
significant variation and range from 8% to 98% [11-
17]. Our study showed decreased serum 25(OH)D 
concentration in all patients. Prevalence of vitamin D 
insufficiency and deficiency were 32.6% and 67.4%, 
respectfully. Many other studies found high 
prevalence of reduced vitamin D concentration in SLE 
patients [10, 11, 15, 18, 19]. In the study of Ruiz-
Irastroza and al., 75% of patients had 25(OH)D less 
than 30 ng/ml and 15% had less than 10 ng/ml [18]. 
The study included 92 patients mostly with a mild form 
of disease, whereby 48% of them didn’t use GC in 
therapy at the time of determination of vitamin D 
status. Canadian study obtained similar data: 66.7% 
of SLE patients had 25(OH)D concentration less than 
80 nmol/l (32 ng/ml), and 17.9% less than 40 nmol/l 
(16 ng/ml) [20]. In a study published in 2011, which 
included 177 patients with SLE treated at a single 
center in Hungary, 81.9% had 25(OH)D concentration 
less than 30 ng/ml [15]. High prevalence of low 
vitamin D concentration is found in a study from Saudi 
Arabia where 98.8% of patients had suboptimal 
vitamin D level. Study included 165 SLE inpatients 
who were compared with 214 healthy subjects in 
control group, where the prevalence of vitamin D 
deficiency was 55% [16]. However, several studies 
have showed low prevalence of vitamin D deficiency. 
Bultink and al. found vitamin D deficiency in only 8% 
of 107 SLE subjects [12]. Differences in study design, 
characteristics of study groups and reference values 
of 25(OH)D make direct comparison between studies 
very difficult. 
Mean serum concentration of 25(OH)D in our 
group of patients was 11.9 ± 7.3 ng/ml (0-25.7 ng/ml). 
These results are similar to those from the group from 
Shanghai (11.5ng/ml) who showed significantly lower 
concentration of 25(OH)D in SLE patients than in 
those with rheumatoid arthritis (54.6 ng/ml) and 
control group (59.2 ng/ml) [21]. In Israeli study from 
2008, serum 25(OH)D concentration was 11.9 ng/ml 
in SLE patients, which was significantly lower than in 
patients with other autoimmune diseases [10]. On the 
other hand, Kamen and al. measured mean serum 
25(OH)D concentration of 21.6 ng/ml in SLE patients 
in a study from 2006 [11].  
Almost half of our patients (47.8%) used 
vitamin D and calcium supplements. Daily dose of 
cholecalciferol in supplements ranged from 400-800 
IU. We found no significant difference in 25(OH)D 
concentration among patients who used supplements 
and those who did not. Similar results were obtained 
in other studies and it seems that these doses of 
supplements do not provide complete protection from 
low vitamin D level and that these patients are also at 
risk for vitamin D deficiency [14, 18, 20, 22]. The 
contributing factor could be also a lack of compliance 
among patients. These results suggest that patients 
with SLE may require higher supplementation dose of 
vitamin D.  
We found no difference in 25(OH)D 
concentration between patients who used 
antimalarials and those who did not, but the value of 
this finding is diminished by the fact that only 19.5% of 
subjects used antimalarials in therapy. Antimalarials 
affect metabolism of vitamin D by inhibiting 1-α-
hydroxylation of 25(OH)D, thereby reducing serum 
concentration of active form of vitamin D [23]. This 
feature of antimalarials is the basis for their use in the 
treatment of 1,25(OH)2D-dependent hypercalcemia in 
granulomatous disease [24]. However, it is not 
completely understood how antimalarials affect 
25(OH)D concentration. Huisman and al. found lower 
1,25(OH)2D concentration in SLE patients treated 
with hydroxychloroquine and no significant difference 
in 25(OH)D concentration among patients who use 
hydroxychloroquine and those who did not [14]. On 
the other hand, Ruiz-Irastroza and al. found higher 
25(OH)D concentration in SEL patients who were 
treated with hydroxychloroquine [18]. 
Long-term GC therapy affects metabolism of 
vitamin D. Animal studies have showed that high 
doses GCs stimulate activity of 24-hydroxylase and 
moderately decrease the activity of 1-alpha-
hydroxylase in the kidneys. However, several studies 
addressing this issue have found both reduced and 
normal 25(OH)D concentration in patients with chronic 
GC therapy [20, 25-27]. In our study, 25(OH)D 
concentration did not correlate either to the current 
GC dose, nor to the length of GC therapy. It should be 
kept in mind that the majority of our subjects used 
moderate to high GC doses and all of them had 
reduced serum 25(OH)D concentration. 
A link between vitamin D deficiency and 
certain clinical manifestations of SLE has been 
suggested in several studies. Kamen and al. found 
that photosensitivity and renal disease are, 
regardeless of race, strong predictors of critically low 
vitamin D level (less than 10 ng/ml) and in the 
Caucasians group the association between discoid 
rash and lower vitamin D level was found [11]. A study 
of SLE patients in Hungary found that those with 
pericarditis, neuropsychiatric manifestations and deep 
venous thrombosis had significantly lower vitamin D 
level [28]. In our study, we did not find an association 
between vitamin D status and skin lesions, 
photosensitivity, arthritis, and lupus nephritis. There 
was a higher prevalence of vitamin D deficiency in a 
group of patients with lupus nephritis, but it was not 
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statistically significant (54.8% vs. 33.3%). Creatinine 
clearance did not correlate with 25(OH)D 
concentration. It is possible that impaired renal 
function leads to accumulation of 25(OH)D which 
overcomes loss of function of 1-α-hydroxylase in the 
kidneys. 
Mean duration of SLE in our patients with 
vitamin D deficiency was 5.1 ± 5.0 years, which was 
less than in vitamin D insufficiency group where mean 
disease duration was 8.3 ± 7.6 years. This difference 
was not statistically significant. Many other studies did 
not find an association between disease duration and 
vitamin D status [18, 20]. It seems that vitamin D 
status is determined more by the way that disease is 
clinically manifested and by applied therapy, rather 
than disease duration. 
A larger number of clinical studies dealt with 
the relationship between vitamin D status and SLE 
activity [8-10, 18, 29]. A study on 165 SLE patients in 
three centers showed significantly greater disease 
activity in patients with severe vitamin D deficiency [8]. 
A similar result was obtained in a group of 46 patients 
from northern and southern Europe [9]. On the other 
hand, several other studies did not find this 
association [10, 18, 21, 29]. Korean authors did not 
find correlation between serum 25(OH)D 
concentration and SLEDAI score and anti-dsDNA Ab 
in a study from 2010 which involved 104 SLE patients 
[29]. In our study, SLEDAI score did not differ 
significantly depending on the vitamin D status. 
Possible reasons for this result are relatively small 
number of subjects and the fact that majority of 
subjects had active disease at the time vitamin D 
status was determined. Also, all patients had reduced 
serum 25(OH)D concentration, so we couldn’t 
compare patients with vitamin D deficiency or 
insufficiency to patients who have sufficent vitamin D.  
Basic studies have shown that vitamin D 
suppresses Th-1 immune response, facilitates 
induction of Foxp3+ regulatory T cells, interruptes the 
process of B lymphocytes differentiation and inhibits 
the production of immunoglobulins and autoantibodies 
[30-32]. One study demonstrated statistically 
significant negative correlation between vitamin D 
level and the presence of IgG anticardiolipin 
antibodies in patients with deep venous thrombosis 
[28]. The same study found statistically significantly 
higher anti-ds-DNA antibodies titer in a group of 
patients with vitamin D deficiency and insufficiency 
compared to patients who were vitamin D sufficient. 
Our results did not show any association between 
vitamin D deficiency and the presence of tested 
autoantibodies (ANA, anti-SSA, anti-ds-DNA, aCL 
IgG, aCL IgM). Patients who had positive anti-ds-DNA 
and anti-SSA antibodies had lower serum 25(OH)D 
concentration, but this difference did not reach 
statistical significance. 
Our study has several limitations. It was 
designed as a cross sectional study with only one 
measurement of serum 25(OH)D concentration. Study 
included patients who generally had a higher level of 
disease activity and it is difficult to transfer these 
results to patients with less active disease. Data on 
prevalence of vitamin D deficiency and insufficiency 
were not compared to demographically appropriate 
control group of healthy patients or with patients with 
other autoimmune rheumatic diseases. The 
advantages of our study is that vitamin D status was 
discussed from different aspects of the SLE, we 
examined relationship with different markers of 
disease activity (SLEDAI, anti-ds-DNA Ab) and 
influence of different medications. To our knowledge 
this is the first such study in patients with SLE in 
Serbia. 
In conclusion, our study shows that vitamin D 
deficiency and insufficiency are common in patients 
with SLE. All of our patients had reduced serum 
25(OH)D concentration: 32.6% had vitamin D 
deficiency, and 67.4% vitamin D insufficiency. There 
was no association of selected clinical manifestations 
and disease activity with vitamin D status. Patients 
who used vitamin D supplements did not have 
significantly higher 25(OH)D level. Further studies are 
needed in order to understand the role of vitamin D 
deficiency in pathogenesis and clinical course of SLE.  
 
 
References 
1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 
357:266-281. 
2. Etten E, Mathieu C. Immunoregulation by 1, 25-
dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol 
Biol. 2005; 97:93-101.  
3. Mora JR, Iwata M, Andrian UH. Vitamin effects on the immune 
system: vitamins A and D take centre stage. Nature Immunol. 
2008; 8: 685-698. 
4. Penna G, Adorinin L. 1,25-dihdroxyvitamin D3 inhibits 
differentiation, maturation, activation and survival of dendritic 
cells leading to impaired alloreactive T cell activation. J 
Immunol. 2000; 164:2405-2411. 
5. Kamen D, Aranow C. Vitamin D in systemic lupus 
erythematosus. Curr Opin Rheum. 2008; 20:532-537. 
6. Lemire JM, Ince A, Takashima M: 1,25-Dihydroxyvitamin D3 
attenuates the expression of experimental murine lupus of 
MRL/l mice. Autoimmunity. 1992; 12:143-148. 
7. Barnes TC, Bucknall RC. Vitamin D deficiency in a patient with 
systemic lupus erythematosus. Rheumatology. 2004; 43:393-
394. 
8. Cutolo M, Otsa K. Vitamin D, immunity and lupus. Lupus. 
2008; 17: 6-10. 
9. Martins DC, Kang J, Kamen DL, et al. The treshold of vitamin 
D required for optimal immune regulation: implications for 
patients with lupus (abstract). Arthritis Rheum. 2006; 54:S431. 
10. Orbach H, Zandman-Goddard G, Amital H, et al. Novel 
biomarkers in autoimmune diseases: prolactin, ferritin, vitamin 
D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci. 
2007; 1109:385-400. 
11. Kamen DL, Cooper GS, Bouali H, Shaftma SR, Hollis BW, 
 Miskovic et al. Vitamin D Status in Patients with Systemic Lupus Erythematosus in Serbia 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2015 Jun 15; 3(2):256-261.                                                                                                                                                                         261 
 
Gilkeson GS. Vitamin D deficiency in systemic lupus 
erythematosus. Autoimmun Rev. 2006; 5:114-117.  
12. Bultinik IE, Lems WF, Kostense PJ et al. Prevalence of and 
risk factors for low bone mineral density and vertebral fractures 
in patients with systemic lupus erythematosus. Arthritis 
Rheum. 2005; 52:2044-2050. 
13. Muller K, Kriegbaum NJ, Baslund B, et al. Vitamin D3 
metabolism in patients with rheumatic diseases: low serum 
levels of 25-hydroxyvitamin D3 in patients with systemic lupus 
erythematosus. Clin Rheumatol. 1995; 14:397-400. 
14. Hiusman AM, White KP, Algra A, et al. Vitamin D levels in 
women with systemic lupus erythematosus and fibromyalgia. J 
Rheumatol. 2001; 28:2535-2539. 
15. Szodoray P, Tarr R, Bazso A, Poor G, Szegedi G, Kiss E. The 
immunopathological role of vitamin D in patients with SLE: 
data from a single centre registry in Hungary. Scan J 
Rheumatol. 2011; 40(2):122-126.  
16. Damanhouri LH. Vitamin D deficiency in Saudi patients with 
systemic lupus erythematosus. Saudi Med J. 2009; 30(10): 
1291-1295. 
17. Bogaczewicz J, Sysa-Jedrzejowska A, Arkuszewska C, Zabek 
J, Kontny E, Wozniacka A. Prevalence of autoantibodies 
directed against 1,25(OH)2D3 in patients with systemic lupus 
erythematosus. Pol Merkur Lekarski. 2010; 28(164):103-107. 
18. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-
Berriotxoa, Aguirre C. Vitamin D deficiency in systemic lupus 
erythematosus: prevalence, predictors and clinical 
consequences. Rheumatology. 2008; 47:920-923. 
19. Thudi A, Yin S, Wandstart AE, Li QZ, Olsen NJ. Vitamin D 
levels and disease status in Texas patients with systemic 
lupus erythematosus. Am J Med Sci. 2008; 335:99-104. 
20. Toloza SMA, Cole DEC, Gladman DD, Ibanez D, Urowitz MB. 
Vitamin D insufficiency in a large female SLE cohort. Lupus. 
2010; 19:13-19. 
21. Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1, 25-
dihydroxyvitamin D3 on human B cell differentiation. J 
Immunol. 2007; 179:1634–1647. 
22. O’Regan S, Chesney RW, Hamstra A, et al. Reduced serum 1, 
25-(OH)2 vitamin D3 levels in prednisone-treated adolescents 
with systemic lupus erythematosus. Acta Paediatr Scand. 
1979; 68:109–111. 
23. Barnes TC, Bucknall RC. Vitamin D deficiency in a patient with 
systemic lupus erythematosus. Rheumatology. 2004; 43:393-
394. 
24. Sharma OP. Hypercalcemia in granulomatosus disorders: a 
clinical review. Curr Opin Pulm Med. 2000; 6:442-447. 
25. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: 
pathogenesis and management. Ann Intern Med. 1990; 112: 
352–364. 
26. Kimberg DV, Baerg RD, Gershon E, Graudusius RT. Effect of 
cortisone treatment on the active transport of calcium by the 
small intestine. J Clin Invest. 1971; 50:1309–1321. 
27. Chesney RW, Mazess RB, Hamstra AJ, DeLuca HF, 
O’Reagan S. Reduction of serum-1, 25-dihydroxyvitamin-D3 in 
children receiving glucocorticoids. Lancet. 1978; 2: 1123–
1125. 
28. Bazso A, Tarr T, Szegedi G, Poor G, Kiss E. 
Immunomodulatory effects of vitamin D in Hungarian SLE 
patients. Bone. [abstract] 2009; S339-S450. 
29. Kim HA, Sung JM, Jeon JY, Yoon JM, Suh CH. Vitamin D may 
not be a good marker of disease activity in Korean patients 
with systemic lupus erythematosus. Rheumatol Int. 
2011;31(9):1189-94. 
30. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-
dihydroxyvitamin D3 receptor in the immune system. Arc 
Biochem Biophys. 2000; 374:334-338. 
31. Bhall AK, Amento EP, Serog B, Glimcher LH. 1,25-
Dihydoxyvitamin D3 inhibits antigen-induced T cell activation. J 
Immunol. 1984; 133:1748-1754. 
32. Linker-Israeli M, Elstner E, Klinenberg JR, et al. Vitamin D(3) 
and its synthetic analogs inhibit the spontaneous in vitro 
immunoglobulin production by SLE derived PBMC. Clin 
Immunol. 2001; 99:82–93.  
